Download PDF
Thromb Haemost 2003; 90(02): 227-234
DOI: 10.1160/TH03-03-0174
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Prevention of thrombosis following deep arterial injury in rats by bovine activated protein C requiring co-administration of bovine protein S

Karl Malm
1   Departments of Plastic and Reconstructive Surgery and Experimental Research,
,
Björn Dahlbäck
2   Department of Laboratory Medicine, Division of Clinical Chemistry, University Hospital, Malmö, Sweden
,
Björn Arnljots
1   Departments of Plastic and Reconstructive Surgery and Experimental Research,
› Author AffiliationsFinancial support: This work was supported by grants from the Swedish Science Council (# 07143), a senior investigator award from the Foundation of Strategic Research (BD) and by research funds from the University Hospital, Malmö (BD, BA).
Further Information

Publication History

Received 23 March 2003

Accepted 02 May 2003

Publication Date:
06 December 2017 (online)

    Permissions and Reprints

Summary

The antithrombotic effect of bovine activated protein C (bAPC) given with or without bovine protein S (bPS) was investigated in a rat model of deep arterial injury. A segment of the left common carotid artery was isolated between vascular clamps and opened longitudinally. An endarterectomy was performed and the arteriotomy was closed with a running suture, whereafter the vessel was reperfused by removing the clamps. The antithrombotic effect (vascular patency rates 31 minutes after reperfusion) and the arteriotomy bleeding were measured. Ten treatment groups each containing 10 rats and a control group of 20 animals were in a blind random fashion given intravenous bolus injections of increasing doses of activated protein C, with or without co-administration of protein S. The groups received either bAPC alone (0.8, 0.4, 0.2 or 0.1 mg/kg), bAPC (0.8, 0.4, 0.2, 0.1 or 0.05 mg/kg) combined with bPS (0.6 mg/kg), or bPS alone (0.6 mg/kg) whereas the control group received vehicle only. Administered alone, bAPC or bPS had no antithrombotic effect, regardless of dosage. In contrast, all groups that were treated with bAPC in combination with bPS demonstrated a significant antithrombotic effect, as compared to controls. Neither bAPC, bPS, nor the combination of bAPC and bPS increased the arteriotomy bleeding significantly compared to controls. In vitro clotting assays using bAPC or bPS alone yielded only minor prolongation of clotting time, whereas bAPC combined with bPS prolonged the clotting time considerably, demonstrating the dependence on the APC-cofactor activity of bPS for expression of anticoagulant activity by bAPC. In conclusion, our study shows the in vivo significance of protein S as a cofactor to activated protein C, and that potent anti-thrombotic effect can be achieved by low doses of bAPC combined with bPS, without producing hemorrhagic side effects.

Keywords

Thrombosis - activated protein C - protein S - bleeding - animal model
 

  • References

  • 1 Dahlback B. Blood coagulation. Lancet 2000; 355: 1627-32.
    CrossrefPubMedGoogle Scholar
  • 2 Dahlback B, Stenflo J. The Protein C Anticoagulant System. In: The Molecular Basis of Blood Diseases Stamatoyannopoulos, Majerus, Perlmutter, Varmus, eds. Saunders WB. 2001; 614-56.
    PubMedGoogle Scholar
  • 3 Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta 2000; 1477: 349-60.
    CrossrefPubMedGoogle Scholar
  • 4 Lane DA, Mannucci PM, Bauer KA. et al. Inherited thrombophilia: Part 1. Thromb Haemost 1996; 76: 651-62.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Lane DA, Mannucci PM, Bauer KA. et al. Inherited thrombophilia: Part 2. Thromb Haemost 1996; 76: 824-34.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-8.
    CrossrefPubMedGoogle Scholar
  • 7 Arnljots B, Dahlback B. Protein S as an in vivo cofactor to activated protein C in prevention of microarterial thrombosis in rabbits. J Clin Invest 1995; 95: 1987-93.
    CrossrefPubMedGoogle Scholar
  • 8 Arnljots B, Dahlback B. Antithrombotic effects of activated protein C and protein S in a rabbit model of microarterial thrombosis. Arterioscler Thromb Vasc Biol 1995; 15: 937-41.
    CrossrefPubMedGoogle Scholar
  • 9 Walker FJ. Regulation of bovine activated protein C by protein S: the role of the cofactor protein in species specificity. Thromb Res 1981; 22: 321-7.
    CrossrefPubMedGoogle Scholar
  • 10 Solymoss S, Tucker MM, Tracy PB. Kinetics of inactivation of membrane-bound factor Va by activated protein C. Protein S modulates factor Xa protection. J Biol Chem 1988; 263: 14884-90.
    CrossrefPubMedGoogle Scholar
  • 11 Tans G, Rosing J, Thomassen MC, Heeb MJ, Zwaal RF, Griffin JH. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 1991; 77: 2641-8.
    CrossrefPubMedGoogle Scholar
  • 12 He X, Dahlback B. Molecular cloning, expression and functional characterization of rabbit anticoagulant vitamin-K-dependent protein S. Eur J Biochem 1993; 217: 857-65.
    CrossrefPubMedGoogle Scholar
  • 13 Rosing J, Hoekema L, Nicolaes GA, Thomassen MC, Hemker HC, Varadi K. et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 27852-8.
    CrossrefPubMedGoogle Scholar
  • 14 Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
    CrossrefPubMedGoogle Scholar
  • 15 Arnljots B, Bergqvist D, Dahlback B. Inhibition of microarterial thrombosis by activated protein C in a rabbit model. Thromb Haemost 1994; 72: 415-20.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Jackson CV, Bailey BD, Shetler TJ. Pharmacological profile of recombinant, human activated protein C (LY203638) in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther 2000; 295: 967-71.
    PubMedGoogle Scholar
  • 17 Foo RS, Gershlick AH, Hogrefe K. et al. Inhibition of platelet thrombosis using an activated protein C-loaded stent: in vitro and in vivo results. Thromb Haemost 2000; 83: 496-502.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Sakamoto T, Ogawa H, Yasue H. et al. Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis. Circulation 1994; 90: 427-32.
    CrossrefPubMedGoogle Scholar
  • 19 Gruber A, Griffin JH, Harker LA, Hanson SR. Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood 1989; 73: 639-42.
    CrossrefPubMedGoogle Scholar
  • 20 Gruber A, Hanson SR, Kelly AB. et al. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation 1990; 82: 578-85.
    CrossrefPubMedGoogle Scholar
  • 21 Araki H, Nishi K, Ishihara N, Okajima K. Inhibitory effects of activated protein C and heparin on thrombotic arterial occlusion in rat mesenteric arteries. Thromb Res 1991; 62: 209-16.
    CrossrefPubMedGoogle Scholar
  • 22 Yamashita T, Matsuoka A, Funatsu A, Yamamoto J. The antithrombotic effect of human activated protein C on He-Ne laser- induced thrombosis in rat mesenteric microvessels. Thromb Res 1994; 75: 33-40.
    CrossrefPubMedGoogle Scholar
  • 23 Smirnov MD, Pyzh MV, Borovikov DV. et al. Low doses of activated protein C delay arterial thrombosis in rats. Thromb Res 1990; 57: 645-50.
    CrossrefPubMedGoogle Scholar
  • 24 Hashimoto M, Watanabe S, Oiwa K. et al. Enhanced thrombolysis induced by argatroban or activated protein C in the presence or absence of staphylokinase, measured in an in vivo animal model using mesenteric arterioles. Haemostasis 2001; 31: 80-9.
    PubMedGoogle Scholar
  • 25 Hashimoto M, Yamashita T, Oiwa K, Watanabe S, Giddings JC, Yamamoto J. Enhancement of endogenous plasminogen activator-induced thrombolysis by argatroban and APC and its control by TAFI, measured in an arterial thrombolysis model in vivo using rat mesenteric arterioles. Thromb Haemost 2002; 87: 110-3.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Stenflo J. A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization. J Biol Chem 1976; 251: 355-63.
    Google Scholar
  • 27 Stenflo J, Jonsson M. Protein S, a new vitamin K-dependent protein from bovine plasma. FEBS Lett 1979; 101: 377-81.
    CrossrefPubMedGoogle Scholar
  • 28 Dahlback B, Hildebrand B, Linse S. Novel type of very high affinity calcium-binding sites in beta- hydroxyasparagine-containing epidermal growth factor-like domains in vitamin K-dependent protein S. J Biol Chem 1990; 265: 18481-9.
    CrossrefPubMedGoogle Scholar
  • 29 Soderstrom T, Hedner U, Arnljots B. Active site-inactivated factor VIIa prevents thrombosis without increased surgical bleeding: topical and intravenous administration in a rat model of deep arterial injury. J Vasc Surg 2001; 33: 1072-9.
    CrossrefPubMedGoogle Scholar
  • 30 Acland RD. Microsurgery Practice Manual. In. Mosby: St Louis; 1980: 58-9.
    Google Scholar
  • 31 Marmur JD, Rossikhina M, Guha A. et al. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest 1993; 91: 2253-9.
    CrossrefPubMedGoogle Scholar
  • 32 Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A 1989; 86: 2839-43.
    CrossrefPubMedGoogle Scholar
  • 33 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134: 1087-97.
    PubMedGoogle Scholar
  • 34 Malm K, Dahlback B, Arnljots B. Low-molecular-weight heparin (Dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury. Plast Reconstr Surg 2003; 111 (05) 1659-66.
    CrossrefPubMedGoogle Scholar